Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Lymphoid 4Dermatologic 3Sarcoma 2Plasma cell 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma, Subependymal 1Glioblastoma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Muromonab-CD3 × CNS × Clear all
NCT00004024 2013-04-05

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
60 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Glioma, Subependymal, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡